

.

Memo to File October 5, 1978

Discussion with Bob Michels and his psychiatry colleagues.

The bottom line is that there is a full recognition of the complementary needs and capabilities and we can go right from there towards the search for appropriate candidates. The repertoire of clinical resources and needs for a more basic research program is full recognized on their side. They have not been able to recruit the kind of people they would want without the additional factors that we could offer. I think it will take some time before our colleagues here understand our responsibilities on our side.

I indicated that the maximum that we probably could commit would be a single tenured professorship given the different connotations that this title has compared to roles across the street. They might be able to generate several additional positions based on somewhat softer or patient care originating funds.

I suggested with general agreement that it would be premature to try to get agreement in principle on this side to the general concept. It would be far better to identify a promising and attractive candidate and the number of these today is rather thin.

We probably should continue to give some consideration to Wyatt but Kety's comments are not all that enthusiastic and in the light of Barchas' review and the recent circum-

VET: Hayop

stances there probably is not too much merit in going ahead right now.

That leaves a rather thin list of tangible candidates but we should probably reexamine the situation with Saul Snyder at least as a consultant and that is one of the tangible step. Kety has already been consulting with Bob Michels not knowing of the Rockefeller connection. Perhaps I should call him up myself and see how he would illuminate it.

Gerry Smith will send me some more background material on a few of their other candidates and I will start trying to indoctrinate myself on the frontiers of this area of investigation. There is a real problem on the extent to which clinical investigation is the primary opportunity for research in biochemical pharmacology as people like Snyder would in fact offer a different emphases. But that is where a discussion with him about research strategies would already be useful and interesting.

Besides Michels, Bill Frosch and Gerry Smith, Kappas was there and of course one of our own responsibilities is to try to figure out our own process in the evaluation of possibilities and opportunities. We should probably have some report of these conversations with our colleagues in the Hospital group in the near future.